JP2023518948A5 - - Google Patents
Info
- Publication number
- JP2023518948A5 JP2023518948A5 JP2022556088A JP2022556088A JP2023518948A5 JP 2023518948 A5 JP2023518948 A5 JP 2023518948A5 JP 2022556088 A JP2022556088 A JP 2022556088A JP 2022556088 A JP2022556088 A JP 2022556088A JP 2023518948 A5 JP2023518948 A5 JP 2023518948A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE2050301-7 | 2020-03-19 | ||
| SE2050301 | 2020-03-19 | ||
| SE2050782 | 2020-06-29 | ||
| SE2050782-8 | 2020-06-29 | ||
| PCT/GB2021/050680 WO2021186185A1 (en) | 2020-03-19 | 2021-03-18 | Novel compounds useful in the treatment and/or prevention of a disease, disorder or condition associated with angiotensin ii |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023518948A JP2023518948A (ja) | 2023-05-09 |
| JPWO2021186185A5 JPWO2021186185A5 (https=) | 2024-03-28 |
| JP2023518948A5 true JP2023518948A5 (https=) | 2024-03-28 |
Family
ID=75339995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022556088A Pending JP2023518948A (ja) | 2020-03-19 | 2021-03-18 | アンギオテンシンｉｉに関連する疾患、障害又は状態の治療及び／又は予防に有用な新規化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230159467A1 (https=) |
| EP (1) | EP4121165A1 (https=) |
| JP (1) | JP2023518948A (https=) |
| KR (1) | KR20230004501A (https=) |
| CN (1) | CN115605265B (https=) |
| AU (1) | AU2021238939A1 (https=) |
| BR (1) | BR112022018549A2 (https=) |
| CA (1) | CA3175559A1 (https=) |
| CL (1) | CL2022002540A1 (https=) |
| CO (1) | CO2022014673A2 (https=) |
| IL (1) | IL296247A (https=) |
| MX (1) | MX2022011613A (https=) |
| PH (1) | PH12022552413A1 (https=) |
| WO (1) | WO2021186185A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4313953A1 (en) * | 2021-03-23 | 2024-02-07 | Vicore Pharma AB | Selective angiotensin ii receptor ligands |
| GB202104033D0 (en) * | 2021-03-23 | 2021-05-05 | Vicore Pharma Ab | New compounds |
| GB202113583D0 (en) * | 2021-09-23 | 2021-11-10 | Vicore Pharma Ab | New compounds |
| MX2024000518A (es) | 2021-07-09 | 2024-01-31 | Vicore Pharma Ab | Nuevos compuestos selectivos de angiotensina ii. |
| JP2024178482A (ja) * | 2021-11-15 | 2024-12-25 | 株式会社アークメディスン | 化合物、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物 |
| IE20230600A3 (en) | 2022-12-22 | 2025-09-24 | Vicore Pharma Ab | A method of treating a patient diagnosed with an interstitial lung disease |
| WO2024149712A1 (en) * | 2023-01-09 | 2024-07-18 | Vicore Pharma Ab | Selective angiotensin ii compounds |
| CN119504723A (zh) * | 2023-08-25 | 2025-02-25 | 武汉人福创新药物研发中心有限公司 | 作为at2r激动剂的噻吩磺酰基氨基甲酸酯 |
| WO2025146172A1 (zh) * | 2024-01-03 | 2025-07-10 | 武汉人福创新药物研发中心有限公司 | 一种并环类化合物作为at2r激动剂 |
| WO2025252142A1 (zh) * | 2024-06-07 | 2025-12-11 | 江苏柯菲平医药股份有限公司 | 一种血管紧张素ii型2受体激动剂及其用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198438A (en) * | 1991-05-07 | 1993-03-30 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| SE9800550D0 (sv) | 1998-02-24 | 1998-02-24 | A & Science Invest Ab | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof |
| KR100938817B1 (ko) * | 2001-05-31 | 2010-01-26 | 바이코어 파마 아베 | 안지오텐신 ⅱ 작용제로 유용한 삼중고리 화합물 |
| CA2449150C (en) | 2001-05-31 | 2011-07-12 | Vicore Pharma Ab | Tricyclic compounds useful as angiotensin ii agonists |
| WO2004046141A1 (en) | 2002-11-21 | 2004-06-03 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| AU2006235698B2 (en) * | 2005-04-12 | 2012-03-29 | Vicore Pharma Ab | New tricyclic angiotensin II agonists |
| US8835471B2 (en) | 2010-06-11 | 2014-09-16 | Vicore Pharma Ab | Use of angiotensin II agonists |
| DE102012004589A1 (de) | 2012-03-09 | 2013-09-12 | Forschungszentrum Jülich GmbH | Agonisten des Angiotensin II AT2-Rezeptors zur Behandlung neurodegenerativer Erkrankungen |
| BR112017012337A2 (pt) | 2014-12-12 | 2018-02-27 | Vicore Pharma Ab | Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação. |
| WO2016107879A2 (en) | 2014-12-30 | 2016-07-07 | Vicore Pharma Ab | New use of angiotensin ii receptor agonists |
| CN107405406A (zh) * | 2015-03-02 | 2017-11-28 | 维科尔药物公司 | 用于治疗肺纤维化的血管紧张素ii受体激动剂 |
| WO2017221012A1 (en) | 2016-06-21 | 2017-12-28 | Vicore Pharma Ab | Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity |
| GB201710906D0 (en) | 2017-07-06 | 2017-08-23 | Vicore Pharma Ab | Compounds and methods for treating peripheral neuropathy |
-
2021
- 2021-03-18 KR KR1020227036148A patent/KR20230004501A/ko active Pending
- 2021-03-18 CN CN202180033927.3A patent/CN115605265B/zh active Active
- 2021-03-18 JP JP2022556088A patent/JP2023518948A/ja active Pending
- 2021-03-18 CA CA3175559A patent/CA3175559A1/en active Pending
- 2021-03-18 EP EP21715951.6A patent/EP4121165A1/en active Pending
- 2021-03-18 BR BR112022018549A patent/BR112022018549A2/pt unknown
- 2021-03-18 MX MX2022011613A patent/MX2022011613A/es unknown
- 2021-03-18 IL IL296247A patent/IL296247A/en unknown
- 2021-03-18 US US17/912,284 patent/US20230159467A1/en active Pending
- 2021-03-18 PH PH1/2022/552413A patent/PH12022552413A1/en unknown
- 2021-03-18 AU AU2021238939A patent/AU2021238939A1/en not_active Withdrawn
- 2021-03-18 WO PCT/GB2021/050680 patent/WO2021186185A1/en not_active Ceased
-
2022
- 2022-09-16 CL CL2022002540A patent/CL2022002540A1/es unknown
- 2022-10-18 CO CONC2022/0014673A patent/CO2022014673A2/es unknown